Development of a scalable commercial model including establishing 10 "centers of excellence" in the U.S. and 10 in Europe utilizing the MUSE™ system by the end of 2014;
Formulation of a clinical advisory board with key opinion leaders in gastroenterology and surgery;
Establishing a sustainable training program involving 'Key Opinion Leaders' in relevant fields;
Rebranding the SRS™ system as the MUSE™ system and enhancing communication;
Increasing presence in target markets, including the recent establishment of a U.S. office in the Bay Area and the appointment of a VP tasked solely with managing the company's European operations;
Ad Statistics
Times Displayed: 50213
Times Visited: 1424 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Expanding local distribution channels in other markets.
"Our ambitious data plan is already making an impact with our target market in the U.S. and Europe and we will continue to drive research that supports MUSE™ as a tool that is as effective and safe when compared to the current surgical treatments," Mr. Rowland said. "MUSE™ may also reduce costs for insurers and hospitals as the procedure is less invasive and can be completed on an outpatient basis. Medigus will continue to provide ongoing commercial and clinical validation regarding MUSE's safety, efficacy and cost value, supported by upcoming data and expected journal publications including abstracts at the 2014 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and Digestive Disease Week (DDW) medical meetings" Mr. Rowland continued.
About Medigus
Medigus is leading the transition from invasive gastric surgery procedures to less invasive, patient-friendly techniques through the development of minimally invasive endoscopic devices and procedures. The company's revolutionary MUSE™ system enables endoscopists to treat gastroesophageal reflux disease (GERD), a chronic disease with increasing global prevalence, by performing a fundoplication procedure through the mouth. Unlike current fundoplication procedures, the MUSE™ system does not require abdominal incisions, which may result in shorter post-procedure recovery. The MUSE™ endoscopy system has received FDA clearance and CE mark. Medigus is traded on the TASE (Tel Aviv Stock Exchange). To learn more about the company's minimally invasive technology platform, please visit http://www.medigus.com/.
#####
Jeff R. Jacomowitz
L A Z A R P A R T N E R S L T D
420 Lexington Avenue, Suite 442
New York, NY 10170
646-871-8481 (direct)
212-867-1762 (main) ext. 481
212-867-0856 (fax)
jrjacomowitz@lazarpartners.com
www.lazarpartners.com
Back to HCB News
